Does DCIS Always Need Surgery?

Surgery remains the standard and primary DCIS treatment, though it isn’t compulsory in every single situation.
Most patients are advised lumpectomy with radiation or a mastectomy, because DCIS can occasionally progress into invasive breast cancer.
For a carefully selected group with low-risk disease, clinical trials are now studying close monitoring instead of immediate surgery.
That approach is still being tested, so it isn’t yet a routine option outside a structured plan.

According to Prof. Dr. Sandeep Nayak, a surgical oncologist who guides patients through DCIS treatment decisions, “DCIS isn’t an emergency, but it isn’t something to ignore either. We can’t yet tell which cases will turn invasive and which will stay put. That’s why surgery stays the standard. Monitoring is a promising idea for the right patient, and it belongs in a proper study or a carefully supervised plan, not a casual decision.”

DCIS sits inside the milk ducts and hasn’t spread into surrounding tissue. Even so, removal is the usual advice.

Unpredictable behaviour: There’s no reliable way yet to tell which DCIS will become invasive. Removing it takes the guesswork out.

Lumpectomy with radiation: The area is removed with a margin of healthy tissue, and radiation afterward roughly halves the chance of local recurrence.

Mastectomy: Advised when DCIS is widespread, sits in more than one area, or is large for the size of the breast. Radiation usually isn’t needed after it.

Hormone therapy: If the DCIS is hormone receptor positive, tamoxifen or an aromatase inhibitor may follow surgery to lower the risk of it returning.

Which route fits depends on how far the DCIS extends on imaging and what the biopsy shows. Our page on breast cancer treatment explains how that assessment is made.

In a small, selected group, possibly. The evidence is still building.

Active monitoring: Regular mammograms and clinical exams in place of an immediate operation. This is being tested in the COMET, LORIS, LORD and LORETTA trials.

Who qualifies: Low risk disease only. Low or intermediate grade, found on screening, no sign of invasion, and usually hormone receptor positive in a woman over 40.

What early results show: In COMET, women who chose monitoring didn’t have more invasive cancer at two years. Longer follow up is still awaited.

Why caution remains: A biopsy can miss a hidden invasive area. In some studies, a minority of women who looked suitable for monitoring had invasive cancer found at surgery.

Drug treatment is a related question for hormone positive disease. Our blog on hormone therapy vs surgery in HR positive breast cancer covers where each one fits.